Antivenin (crotalidae) polyvalent - Biologic Drug Details

Summary for antivenin (crotalidae) polyvalent

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antivenin (crotalidae) polyvalent Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antivenin (crotalidae) polyvalent Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for antivenin (crotalidae) polyvalent Derived from Patent Text Search

No patents found based on company disclosures

Antivenin (crotalidae) polyvalent Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Antivenin (Crotalidae) Polyvalent

Introduction to Antivenin (Crotalidae) Polyvalent

Antivenin (crotalidae) polyvalent, also known as pit viper antivenin, is a biologic drug used to treat bites from certain poisonous snakes, including rattlesnakes, copperheads, and cottonmouth moccasins. This medication belongs to a group of immunizing agents and is crucial in regions with a high presence of venomous species.

Market Size and Growth Projections

The global antivenom market, which includes antivenin (crotalidae) polyvalent, is anticipated to experience significant growth over the coming years. The market is expected to reach USD 1.20 billion by 2024 and grow at a Compound Annual Growth Rate (CAGR) of 3.13% to reach USD 1.40 billion by 2029[3].

Key Market Trends

Polyvalent Antivenoms Segment Growth

The polyvalent antivenoms segment, which includes antivenin (crotalidae) polyvalent, is poised to register robust growth. Polyvalent antivenoms are beneficial because they can counteract several homologous venoms from various species/genera, making them particularly useful in regions with multiple venomous species and when the culprit snake is unknown[1][3][5].

Advantages of Polyvalent Antivenoms

Polyvalent antivenoms offer several advantages:

• They can save lives even when the specific snake is unknown.
• They are less expensive and easier to produce and handle compared to monovalent antivenoms.
• They have been formulated with high potencies analogous to those of monovalent antivenoms, causing few and minor adverse reactions[1][3][5].

Cost-Effectiveness and Clinical Protocols

Clinical Protocol Implementation

Studies have shown that implementing clinical protocols for the use of polyvalent antivenoms, such as Crotalidae polyvalent immune Fab antivenom (FabAV), can be highly cost-effective. A clinical protocol adopted at an academic medical center resulted in the use of significantly fewer vials of FabAV, leading to a cost savings of approximately $2000 per patient. Additionally, patients treated under this protocol had shorter hospital stays without an increase in adverse events or envenomation progression[2].

Economic Impact

The cost-effectiveness of polyvalent antivenoms is a significant factor driving their adoption. By reducing the number of vials required and shortening hospital stays, these antivenoms can significantly lower healthcare costs associated with snakebite treatments.

Market Drivers

Rising Research and Development

The antivenom market is driven by increasing research and development activities. Studies, such as those published in Toxin Basel, have shown positive results for polyvalent antivenoms in preventing or reversing myotoxicity induced by various snake venoms. This ongoing research further validates the efficacy of existing treatments and encourages the development of new polyvalent antivenoms[3][5].

Geographic Demand

Regions with a high presence of venomous species are key markets for polyvalent antivenoms. These regions often face challenges in producing monovalent antivenoms for each species, making polyvalent antivenoms a more practical and effective solution[1][3][5].

Key Players and Market Competition

The antivenom market includes several key players such as Pfizer Inc., CSL Limited, BTG PLC, Merck & Co., and Flynn Pharma. These companies are focusing on developing and improving polyvalent antivenoms due to their numerous advantages and growing demand[1].

Regulatory and Safety Considerations

Safety Profile

Polyvalent antivenoms, like pit viper antivenin, are generally well-tolerated but can cause side effects such as difficulty in breathing, hives, itching, and swelling. There is also a risk of serum sickness, which can occur up to 24 days after treatment. However, with good manufacturing processes, these antivenoms have been shown to cause few and minor adverse reactions[4].

Regulatory Oversight

The use of antivenoms is strictly regulated and must be administered under the supervision of a doctor. Regulatory bodies ensure that these medications meet stringent safety and efficacy standards before they are approved for use.

Financial Trajectory

The financial trajectory of the antivenom market, particularly the polyvalent segment, is positive due to several factors:

• Growing Demand: The increasing incidence of snakebites in various regions and the preference for polyvalent antivenoms drive market growth.
• Cost-Effectiveness: The reduction in healthcare costs associated with the use of polyvalent antivenoms contributes to their financial viability.
• Research and Development: Ongoing research validating the efficacy of polyvalent antivenoms and improving their formulations further supports market growth[1][3][5].

Conclusion

The market for antivenin (crotalidae) polyvalent is poised for significant growth driven by its advantages in treating snake envenomations, especially in regions with multiple venomous species. The cost-effectiveness, safety profile, and ongoing research and development activities all contribute to the positive financial trajectory of this segment.

Key Takeaways

• The global antivenom market is expected to reach USD 1.40 billion by 2029.
• Polyvalent antivenoms are preferred due to their ability to counteract multiple venoms and lower production costs.
• Clinical protocols can significantly reduce healthcare costs and improve patient outcomes.
• Key players are focusing on developing and improving polyvalent antivenoms.
• Regulatory oversight ensures the safety and efficacy of these medications.

FAQs

Q: What is the primary advantage of polyvalent antivenoms over monovalent antivenoms?

A: Polyvalent antivenoms can counteract multiple venoms from different species, making them more practical in regions with numerous venomous species and when the specific snake is unknown.

Q: How do clinical protocols impact the use of polyvalent antivenoms?

A: Clinical protocols can reduce the number of vials required, leading to cost savings and shorter hospital stays without increasing adverse events.

Q: Which regions are the key markets for polyvalent antivenoms?

A: Regions with a high presence of venomous species, where producing monovalent antivenoms for each species is challenging, are the key markets.

Q: What are the common side effects of pit viper antivenin?

A: Common side effects include difficulty in breathing, hives, itching, swelling, and the risk of serum sickness up to 24 days after treatment.

Q: Who are the key players in the antivenom market?

A: Key players include Pfizer Inc., CSL Limited, BTG PLC, Merck & Co., and Flynn Pharma, among others.

Sources

1. Insights on the Anti-venom Global Market to 2025 - ResearchAndMarkets.com
2. Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom - PubMed
3. Anti Venom Market - Trends, Growth & Size - Mordor Intelligence
4. Antivenin (crotalidae) polyvalent (injection route) - Mayo Clinic
5. Anti-venom Market Trends - Mordor Intelligence